Drug intelligence / Profile preview

PF-0713

Development stage: Unknown
Lead developer: Ensysce Biosciences
Modality: Small Molecules
Administration: Intravenous

Overview

PF-0713 is an investigational **small-molecule intravenous sedative-hypnotic** and **GABAA receptor agonist** designed as a propofol-related anesthetic agent. It was reported as being initially developed by Ensysce Biosciences for use in **general anesthesia, ICU sedation, procedural sedation, and potentially chemotherapy-related sedation**, with the goal of improving pharmacodynamic and pharmacokinetic properties relative to propofol. Available context indicates that PF-0713 entered **Phase 1 clinical testing** in healthy volunteers to assess safety, pharmacokinetics, and pharmacodynamics after single intravenous administration.

Other names: 1083093-47-3

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on PF-0713.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-0713.

Explore the full profile